IDT surprised by Virax claim
27 May, 2003 by Jeremy TorrA claim from Virax Holdings that it had been approached by Melbourne company Institute of Drug Technology with a view to a full takeover, has taken IDT managing director Graeme Blackman by surprise.
Dow boosts nanotech interests with Starpharma subsidiary appointments
27 May, 2003 by Melissa TrudingerUS giant Dow Corning's investment in Australian nanotechnology has deepend with a series of high-profile Dow-related appointments to the board and management of Starpharma's US subsidiary Dendritic Nanotechnologies.
Humira gets the nod in Europe
23 May, 2003 by Jeremy TorrPeptech-licensed monoclonal antibody Humira, produced by pharma Abbott, has been granted a positive opinion for the treatment of rheumatoid arthritis in Europe.
Love-ins and protests over, it's down to work for new Qld precinct
22 May, 2003 by Pete YoungThe newest superstar among Australian life science research centres, the Queensland Bioscience Precinct, is getting down to business after an official opening that was part love-in, part confrontation.
Xcelerator appointment sets stage for push into Asia
22 May, 2003 by Jeremy TorrSydney based biotech incubator Xcelerator has beefed up its board with an old Asia hand in the form of ex-Johnson & Johnson chairman Michael Yates.
IATIA will use Bio-Rad partnership to focus on AP
22 May, 2003 by Jeremy TorrA recent deal with Bio-Rad Asia-Pacific has seen Melbourne bio-optical equipment makers IATIA expand sales into an impressive 17 countries throughout the region.
Gradipore still filtering applicants for top job
22 May, 2003 by Jeremy TorrTime is not on Gradipore's side. Not only has its separation technology been delayed by production problems, but it still hasn't found a replacement CEO for the trouble-shooting Bob Lieb, who officially departs at the end of this week.
Federal science spending hits new heights
19 May, 2003 by Simon GroseThe federal government is showing no signs of backing away from its Backing Australia's Ability program -- and there could be more good news to come.
Melbourne industry group launches strategy
08 May, 2003 by Melissa TrudingerRecently-formed alliance The BioMelbourne Network has unveiled its action agenda for driving the Victorian biotechnology sector forward, focusing on building networks between science, government and business, and promoting Melbourne as a regional hub for the industry.
NSW companies dominate fourth-round BIF funding
01 May, 2003 by Pete YoungMore than 40 organisations -- nearly half of them in NSW -- will share nearly $AUD10 million from the fourth round of the federal government's Biotechnology Innnovation Fund (BIF) grants announced today.
Researchers explore biosensor applications for fluorescence discovery
28 April, 2003 by Melissa TrudingerA coral protein with an intense blue colour has properties that could prove useful as a biological probe to track interactions between proteins and cells, according to new research from Monash and Queensland universities.
Making IT headlines
28 April, 2003 by Eve EpsteinBob Palermini got his first taste of Unix some 25 years ago when he became involved in production at a small newspaper that used the system to set type. Although he started out as an editor, Palermini was hooked on IT after that initial experience and taught himself the skills to make the transition to the technology side of the business. “Early on it was trial and error and books,” he says.
The ones to watch
24 April, 2003 by Melissa TrudingerMelissa Trudinger takes a look at the emerging biotech clusters in Perth and Adelaide.
Value of deals overrated: KPMG
23 April, 2003 by Melissa TrudingerDoing deals is one of the cornerstones of biotechnology, and can cover a myriad of activities from obtaining private or public equity, to collaborations and joint ventures, and in- and out-licensing of technology and products. But while transactions can increase the value of a company, too often the deal itself can lead to a decline in shareholder value.
Eiffel wooed by US VC agents
22 April, 2003 by Jeremy TorrIn what it hopes is the first step towards a Nasdaq listing, Melbourne platform technology biotech Eiffel Technologies has appointed New York-based introduction agents Global Markets Capital Corporation (GMCC) to represent it on the US investor market.
